Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Ceftolozane/tazobactam safe, effective in complicated UTI
Combination therapy with ceftolozane and tazobactam demonstrates a favourable safety profile in children with complicated urinary tract infection (cUTI) similar to that of meropenem and to the previously reported safety profile in adults with cUTI, a study has shown.
Ceftolozane/tazobactam safe, effective in complicated UTI
30 Mar 2023Remdesivir cuts mortality in COVID-19 patients requiring no or low-flow oxygen
In a systematic review and individual patient data meta-analysis, the broad-spectrum antiviral agent remdesivir reduced mortality in adult patients hospitalized for COVID-19 who did not require oxygen support or only required low-flow supplementation when the need for oxygen arose.
Remdesivir cuts mortality in COVID-19 patients requiring no or low-flow oxygen
30 Mar 2023How to differentiate COVID-19 pneumonia from influenza and bacterial pneumonia on CT?
Arched bridge and/or vacuole signs on CT may support a diagnosis of COVID-19 pneumonia and assist in differentiation from influenza and bacterial pneumonia, a retrospective study by the Chinese University of Hong Kong has revealed.
How to differentiate COVID-19 pneumonia from influenza and bacterial pneumonia on CT?
28 Mar 2023COVID-19 vaccine risk-benefit ratio favourable for patients with rheumatic diseases
In the CONVIN-SING* study, there was a favourable risk-benefit ratio for COVID-19 vaccination in individuals with autoimmune inflammatory rheumatic diseases (AIIRD) who have received a COVID-19 mRNA vaccine.
COVID-19 vaccine risk-benefit ratio favourable for patients with rheumatic diseases
28 Mar 2023CAB+RPV LA vs B/FTC/TAF for HIV: Which is better?
In virologically suppressed adults with HIV, the cabotegravir + rilpivirine long-acting (CAB+RPV LA) regimen was on par with bictegravir/emtricitabine/tenofovir alafenamide (B/FTC/TAF) in terms of virologic efficacy, but the former gained the upper hand over the latter in terms of patient satisfaction and preference, the SOLAR* study reports.
CAB+RPV LA vs B/FTC/TAF for HIV: Which is better?
27 Mar 2023Full anticoagulation dosing confers survival advantage in hospitalized COVID-19 patients
A full, therapeutic dosing of anticoagulation flops for reducing the incidence of overall combined outcomes in noncritically ill patients hospitalized with COVID-19 as compared with prophylactic dosing, although there is a signal of benefit for mortality and disease progression with the therapeutic dosing, as shown in the FREEDOM COVID trial presented at ACC.23/WCC.
Full anticoagulation dosing confers survival advantage in hospitalized COVID-19 patients
23 Mar 2023Neurologic disability predicts severe ED in men infected with HTLV-1
Patients with human T-lymphotropic virus 1 (HTLV-1) infection may develop erectile dysfunction (ED), and time to progression to its severe form is significantly associated with the degree of neurologic compromise at baseline, reveals a study.